PD-1 and CTLA-4 alone or in combination have been very successful and are approved for the treatment of metastatic melanoma and advanced PD-L1-positive non-small cell lung cancer (NSCLC) [51,52,53,54,55]. This evidence concerns the gene CTLA4 and metastatic melanoma.